SG11201906871XA - Rorgamma modulators and uses thereof - Google Patents

Rorgamma modulators and uses thereof

Info

Publication number
SG11201906871XA
SG11201906871XA SG11201906871XA SG11201906871XA SG11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA
Authority
SG
Singapore
Prior art keywords
international
diseases
rorgamma
pct
rue
Prior art date
Application number
SG11201906871XA
Inventor
Jean-François Delhomel
Enrico Perspicace
Zouher Majd
Peggy Parroche
Robert Walczak
Pascal Bonnet
Jade Fogha
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11201906871XA publication Critical patent/SG11201906871XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WIP0 I PCT oimitia °nolo 01110ll mil 0l IIIIIIIII111110 DIIIIII (10) International Publication Number WO 2018/138356 Al (51) International Patent Classification: CO7D 405/14 (2006.01) A61P 37/02 (2006.01) CO7D 405/12 (2006.01) A61P 29/00 (2006.01) A61K 31/506 (2006.01) A61P 3/00 (2006.01) A61K 31/4427 (2006.01) (21) International Application Number: PCT/EP2018/052163 (22) International Filing Date: 29 January 2018 (29.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305091.5 27 January 2017 (27.01.2017) EP 17178889.6 29 June 2017 (29.06.2017) EP (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). (72) Inventors: DELHOMEL, Jean-Francois; 79 avenue du President JF Kennedy, 62000 ARRAS (FR). PERSPI- CACE, Enrico; 1 me Maurice SCHUMANN, 59133 PHALEMPIN (FR). MAJD, Zouher; 29 rue Nationale, 59320 ENNETIERES-EN-WEPPES (FR). PARROCHE, Peggy; 9 rue des Brigittines, 59800 LILLE (FR). WAL- CZAK, Robert; Residence Parc d'Isly, 13B rue Delezenne, 59000 LILLE (FR). BONNET, Pascal; 349 Allee des Per- venches, 45160 OLIVET (FR). FOGHA, Jade; 45 me des Hauts Champs, 45000 ORLEANS (FR). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (74) Agent: CABINET BECKER ET ASSOCIES; 25, me Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 1-1 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 00 1-1 (54) Title: RORGAMMA MODULATORS AND USES THEREOF (57) : The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharma- O ceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has \" therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fl- 0 brotic diseases, or cholestatic diseases.
SG11201906871XA 2017-01-27 2018-01-29 Rorgamma modulators and uses thereof SG11201906871XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305091 2017-01-27
EP17178889 2017-06-29
PCT/EP2018/052163 WO2018138356A1 (en) 2017-01-27 2018-01-29 Rorgamma modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11201906871XA true SG11201906871XA (en) 2019-08-27

Family

ID=61017942

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906871XA SG11201906871XA (en) 2017-01-27 2018-01-29 Rorgamma modulators and uses thereof

Country Status (14)

Country Link
US (2) US11160801B2 (en)
EP (1) EP3573974A1 (en)
JP (1) JP7138647B2 (en)
KR (1) KR20190112009A (en)
CN (1) CN110177782A (en)
AU (1) AU2018212618A1 (en)
BR (1) BR112019015399A2 (en)
CA (1) CA3050045A1 (en)
IL (1) IL268150A (en)
MX (1) MX2019008920A (en)
PH (1) PH12019501683A1 (en)
SG (1) SG11201906871XA (en)
WO (1) WO2018138356A1 (en)
ZA (1) ZA201905513B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023006193A (en) 2020-11-26 2023-06-09 Jiangsu Hengrui Pharmaceuticals Co Ltd Fused tricyclic compound, preparation method therefor and application thereof in medicine.
WO2022242724A1 (en) 2021-05-19 2022-11-24 上海迪诺医药科技有限公司 Nitrogen-containing compound, conjugate containing said compound, and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036375A1 (en) 2001-08-30 2004-09-01 Novartis Ag PIRROLO [2,3-D] PIRIMIDINE -2- CARBONITRILE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES
AR059224A1 (en) 2006-01-31 2008-03-19 Jerini Ag COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
US10035790B2 (en) * 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
WO2016102633A1 (en) 2014-12-23 2016-06-30 Genfit Heterocyclic derivatives as rorgamma modulators
WO2017010399A1 (en) * 2015-07-10 2017-01-19 塩野義製薬株式会社 COMPOUNDS HAVING RORγt INHIBITORY EFFECTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Also Published As

Publication number Publication date
US11974997B2 (en) 2024-05-07
BR112019015399A2 (en) 2020-03-31
US20190388414A1 (en) 2019-12-26
CN110177782A (en) 2019-08-27
CA3050045A1 (en) 2018-08-02
IL268150A (en) 2019-09-26
AU2018212618A1 (en) 2019-08-29
JP7138647B2 (en) 2022-09-16
WO2018138356A1 (en) 2018-08-02
JP2020505412A (en) 2020-02-20
MX2019008920A (en) 2019-12-09
US20220133716A1 (en) 2022-05-05
PH12019501683A1 (en) 2020-06-15
KR20190112009A (en) 2019-10-02
US11160801B2 (en) 2021-11-02
EP3573974A1 (en) 2019-12-04
ZA201905513B (en) 2020-05-27

Similar Documents

Publication Publication Date Title
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201909168VA (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
SG11201811432WA (en) Rna for cancer therapy
SG11201907034PA (en) Methods of treating influenza
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201906803WA (en) N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901817SA (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201809882XA (en) Pharmaceutical combinations for treating cancer